Journal
ONCOTARGET
Volume 7, Issue 52, Pages 86239-86256Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.13369
Keywords
acute myeloid leukemia; aurora kinase; FLT3; quinazoline; multi-kinase inhibitor
Categories
Funding
- National Health Research Institutes, Ministry of Science and Technology, Taiwan [BP-104-PP-03, MOST-101-2113-M-400-002-MY4, MOST-103-2325-B-400-021-, MOST-102-2113-M-400-003-MY3]
- Science and Engineering Research Board, Government of India [SR/FT/LS-64/2011]
- Ministry of Science and Technology, Taiwan
Ask authors/readers for more resources
The design and synthesis of a quinazoline-based, multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and other malignancies is reported. Based on the previously reported furanopyrimidine 3, quinazoline core containing lead 4 was synthesized and found to impart dual FLT3/AURKA inhibition (IC50 = 127/5 nM), as well as improved physicochemical properties. A detailed structure-activity relationship study of the lead 4 allowed FLT3 and AURKA inhibition to be finely tuned, resulting in AURKA selective (5 and 7; 100-fold selective over FLT3), FLT3 selective (13; 30-fold selective over AURKA) and dual FLT3/AURKA selective (BPR1K871; IC50 = 19/22 nM) agents. BPR1K871 showed potent anti-proliferative activities in MOLM-13 and MV4-11 AML cells (EC50 similar to 5 nM). Moreover, kinase profiling and cell-line profiling revealed BPR1K871 to be a potential multi-kinase inhibitor. Functional studies using western blot and DNA content analysis in MV4-11 and HCT-116 cell lines revealed FLT3 and AURKA/B target modulation inside the cells. In vivo efficacy in AML xenograft models (MOLM-13 and MV4-11), as well as in solid tumor models (COLO205 and Mia-PaCa2), led to the selection of BPR1K871 as a preclinical development candidate for anticancer therapy. Further detailed studies could help to investigate the full potential of BPR1K871 as a multi-kinase inhibitor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available